MTOR and Alzheimer disease: Based on these findings, pharmacological agents that can modulate the AMPK/mTOR/IRF5 signaling pathway may inhibit microglial activation, thereby offering significant therapeutic potential for alleviating neuroinflammation and neuronal cell senescence in patients with neurodegenerative diseases, such as AD.